Data / Drug companies / Bajaj Healthcare Ltd
Bajaj Healthcare Ltd: 14 products in the FDA NDC directory, labeler code 84855
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bajaj Healthcare Ltd (labeler code 84855) lists 14 products in the FDA National Drug Code Directory. By type: 14 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on May 20, 2026.
The request: Watch Bajaj Healthcare Ltd (FDA labeler code 84855): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 84855
- Products in commercial distribution
- 14
- Packages
- 16
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- February 12, 2024
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 14 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 14 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 11 | 78.6% |
| Liquid | 3 | 21.4% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Metronidazole benzoate | 84855-014 | Powder | Bulk ingredients | May 20, 2026 |
| Metronidazole benzoate | 84855-016 | Powder | Bulk ingredients | June 5, 2025 |
| Fluoxetine hydrochloride | 84855-013 | Powder | Bulk ingredients | December 30, 2024 |
| Carbamazepine | 84855-010 | Powder | Bulk ingredients | December 30, 2024 |
| Lactulose solution | 84855-008 | Liquid | Bulk ingredients | December 30, 2024 |
| Lactulose concentrated | 84855-007 | Liquid | Bulk ingredients | December 30, 2024 |
| Cetirizine hydrochloride | 84855-006 | Powder | Bulk ingredients | December 30, 2024 |
| Chlorhexidine gluconate solution | 84855-004 | Liquid | Bulk ingredients | December 12, 2024 |
| Rivaroxaban | 84855-012 | Powder | Bulk ingredients | December 7, 2024 |
| Octenidine dihydrochloride | 84855-009 | Powder | Bulk ingredients | December 7, 2024 |
| Oxcarbazepine | 84855-005 | Powder | Bulk ingredients | December 7, 2024 |
| Chlorhexidine base | 84855-002 | Powder | Bulk ingredients | December 7, 2024 |
| Apixaban | 84855-001 | Powder | Bulk ingredients | December 2, 2024 |
| Ascorbic acid | 84855-015 | Powder | Bulk ingredients | February 12, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.